查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1400581

乳房切片设备市场规模-按产品（针式乳房切片枪、乳房切片引导系统、针和镊子）、技术（影像引导切片、液体切片）、最终用途-全球预测（2023-2032）

Breast Biopsy Devices Market Size - By Product (Needle Based Breast Biopsy Guns, Breast Biopsy Guidance Systems, Needle, & Forceps), Technique (Image Guided Biopsy, Liquid Biopsy), End-use - Global Forecast (2023-2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 679 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于全球乳癌发生率不断上升，推动了对先进诊断技术的需求，预计 2023 年至 2032 年间，乳房切片设备市场规模的CAGR将超过 6.8%。根据 NBCC 的数据，2023 年，女性诊断出约 297,790 例新的侵袭性乳癌病例，男性诊断出 2,800 例新病例。

随着宣传活动和筛检计画变得越来越普遍，医疗保健提供者优先考虑采用先进的活检设备，以提高乳癌诊断的效率和精确度。

真空辅助活检和超音波引导活检等微创技术的发展减少了患者的不适和手术併发症，从而提高了采用率。此外，成像技术的创新以及影像判读人工智慧（AI）的整合有助于提高诊断准确性，刺激市场成长。

整个乳房切片设备市场根据产品、技术、最终用途和地区进行分类。

在引入非侵入性和高度敏感的诊断方法的支持下，液体活检细分市场预计将在 2023 年和 2032 年显着增长。这种创新方法涉及分析循环肿瘤 DNA (ctDNA) 或血液中存在的其他生物标记物，以检测和监测各种癌症。该技术补充了传统的组织活检，为监测治疗反应和识别基因突变提供了一种侵入性较小的替代方案。早期检测能力以及对疾病进展的即时监测正在推动液体活检的采用。

由于采用精简高效的乳房切片环境，门诊手术中心 (ASC) 将在 2023 年至 2032 年期间为市场带来可观的收入。门诊手术中心的集中性质可以加快患者周转速度、减少等待时间并优化调度，有助于提高手术效率。此外，由于其便利性、个人化护理和成本效益，患者通常更喜欢 ASC 进行乳房活检手术。

由于乳癌盛行率不断上升以及加强早期检测的持续努力，欧洲乳房切片设备产业规模预计到 2032 年将显着增长。对女性健康和健全的医疗基础设施的重视导致复杂的乳房活检设备的广泛采用。影像技术和微创活检技术的整合等技术进步透过提高诊断准确性和患者体验进一步刺激区域市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：乳房切片设备产业洞察

  • COVID-19 影响分析
  • 产业生态系统分析
  • 技术景观
  • 监管环境
  • 产业影响力
    • 成长动力
      • 乳癌发生率增加
      • 乳房切片设备的技术进步
      • 对乳癌筛检的认识不断提高
      • 有利的报销方案
    • 产业陷阱与挑战
      • 与乳房切片手术相关的高成本
      • 与使用活检针相关的感染风险
  • 成长潜力分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
    • Hologic Inc
    • Devicor Medical Products, Inc. (Danaher Corporation)
    • Becton, Dickinson and Company (BD)
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：乳房切片设备市场规模与预测：按产品分类，2018-2032 年

  • 主要动向：按产品
  • 乳房切片引导系统
    • 手动的
    • 机器人
  • 乳腺针切片枪
    • 真空辅助活检 (VAB) 装置
    • 细针抽吸切片检查 (FNAB) 装置
    • 空心针切片检查 (CNB) 装置
  • 乳房切片针
    • 一次性的
    • 可重复使用的
  • 乳腺切片钳
    • 普通活检钳
    • 热活检钳
  • 其他产品
    • 刷子
    • 刮匙
    • 拳击

第 6 章：乳房切片设备市场规模与预测：按技术分类，2018-2032 年

  • 主要动向：按技术
  • 影像引导活检
    • MRI导引乳房切片检查
    • 超音波引导乳房切片检查
    • 乳房X光摄影引导立体定位活检
    • 其他影像引导活检
  • 液体活检
    • 基于NGS的活检
    • 基于PCR的活检
    • 基于微阵列的活检

第 7 章：乳房切片设备市场规模与预测：依最终用途，2018-2032 年

  • 主要动向：依最终用途
  • 医院
  • 门诊手术中心
  • 其他最终用户

第 8 章：乳房切片设备市场规模与预测：按地区划分，2018-2032 年

  • 主要动向：按地区
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Stryker Corporation
  • Boston Scientific Corporation
  • FUJIFILM Holdings Corporation
  • Argon Medical Devices, Inc
  • Hologic Inc
  • Cook Group Incorporated
  • Becton, Dickinson and Company (BD)
  • Medtronic plc
  • Olympus Corporation
  • Cardinal Health
  • INRAD Inc
  • Danaher Corporation
  • B. Braun Melsungen AGS
简介目录
Product Code: 7441

Breast Biopsy Devices Market size is estimated to record a CAGR of over 6.8% between 2023 and 2032, driven by the increasing incidence of breast cancer across the globe propelling the demand for advanced diagnostic technologies. As per NBCC, in 2023, around 297,790 new cases of invasive breast cancer were diagnosed in women, and 2,800 new cases diagnosed in men.

As awareness campaigns and screening programs become more prevalent, healthcare providers prioritize the incorporation of sophisticated biopsy devices to enhance the efficiency and precision of breast cancer diagnosis.

The development of minimally invasive techniques, such as vacuum-assisted biopsy and ultrasound-guided biopsy, reduces patient discomfort and procedural complications, leading to increased adoption. Moreover, innovations in imaging technologies and the integration of artificial intelligence (AI) for image interpretation contribute to higher diagnostic accuracy, stimulating the market growth.

The overall breast biopsy devices market is classified on the basis of product, technique, end-use, and region.

Liquid biopsy segment is poised for a notable growth during 2023 and 2032, backed by introduction of non-invasive and highly sensitive diagnostic methods. This innovative approach involves analyzing circulating tumor DNA (ctDNA) or other biomarkers present in the blood to detect and monitor various cancers. The technique complements traditional tissue biopsies, offering a less invasive alternative for monitoring treatment responses and identifying genetic mutations. The early detection capabilities, along with the real-time monitoring of disease progression is pushing the adoption of liquid biopsy.

Ambulatory surgical centers (ASCs) will generate notable revenues for the market during 2023-2032, favored by streamlined and efficient environment for performing breast biopsies. The focused nature of ambulatory surgical centers allows for quicker patient turnaround, reduced waiting times, and optimized scheduling, contributing to increased procedural efficiency. Moreover, patients often prefer ASCs for breast biopsy procedures due to the convenience, personalized care, and cost-effectiveness.

Europe breast biopsy devices industry size is slated to witness a significant growth through 2032, owing to the increasing prevalence of breast cancer and the continuous efforts to enhance early detection. The emphasis on women's health and robust medical infrastructure is leading to a widespread incorporation of sophisticated breast biopsy devices. Technological advancements, such as the integration of imaging technologies and minimally invasive biopsy techniques, further stimulate regional market growth by improving diagnostic accuracy and patient experience.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & workings
  • 1.3 Forecast calculations
  • 1.4 Data Sources
    • 1.4.1 Primary
    • 1.4.2 Secondary
      • 1.4.2.1 Paid sources
      • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Global breast biopsy devices market 360 degree synopsis, 2018 - 2032
    • 2.1.1 Regional trends
    • 2.1.2 Product trends
    • 2.1.3 Technique trends
    • 2.1.4 End-use trends

Chapter 3 Breast Biopsy Devices Industry Insights

  • 3.1 COVID- 19 impact analysis
  • 3.2 Industry ecosystem analysis
  • 3.3 Technology landscape
  • 3.4 Regulatory landscape
  • 3.5 Industry impact forces
    • 3.5.1 Growth drivers
      • 3.5.1.1 Increasing incidence of breast cancer
      • 3.5.1.2 Technological advancements in breast biopsy equipment
      • 3.5.1.3 Rising awareness regarding breast cancer screening
      • 3.5.1.4 Favourable reimbursement scenario
    • 3.5.2 Industry pitfalls & challenges
      • 3.5.2.1 High cost associated with breast biopsy procedure
      • 3.5.2.2 Risk of infection associated with the use of biopsy needles
  • 3.6 Growth potential analysis
    • 3.6.1 By product
    • 3.6.2 By technique
    • 3.6.3 By end-use
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
    • 4.1.1 Hologic Inc
    • 4.1.2 Devicor Medical Products, Inc. (Danaher Corporation)
    • 4.1.3 Becton, Dickinson and Company (BD)
  • 4.2 Competitive analysis of major market players, 2022
  • 4.3 Competitive positioning matrix, 2022
  • 4.4 Strategic outlook matrix, 2022

Chapter 5 Breast Biopsy Devices Market Size and Forecast, By Product, 2018-2032 (USD Million & Units)

  • 5.1 Key trends, by product
  • 5.2 Breast biopsy guidance systems
    • 5.2.1 Manual
    • 5.2.2 Robotic
  • 5.3 Needle based breast biopsy guns
    • 5.3.1 Vacuum-assisted biopsy (VAB) devices
    • 5.3.2 Fine needle aspiration biopsy (FNAB) devices
    • 5.3.3 Core needle biopsy (CNB) devices
  • 5.4 Breast biopsy needles
    • 5.4.1 Disposable
    • 5.4.2 Reusable
  • 5.5 Breast biopsy forceps
    • 5.5.1 General biopsy forceps
    • 5.5.2 Hot biopsy forceps
  • 5.6 Other products
    • 5.6.1 Brushes
    • 5.6.2 Curettes
    • 5.6.3 Punches

Chapter 6 Breast Biopsy Devices Market Size and Forecast, By Technique, 2018-2032 (USD Million)

  • 6.1 Key trends, by technique
  • 6.2 Image guided biopsy
    • 6.2.1 MRI guided breast biopsy
    • 6.2.2 Ultrasound guided breast biopsy
    • 6.2.3 Mammography guided stereotactic biopsy
    • 6.2.4 Other image guided biopsies
  • 6.3 Liquid Biopsy
    • 6.3.1 NGS based biopsy
    • 6.3.2 PCR based biopsy
    • 6.3.3 Micro-array based biopsy

Chapter 7 Breast Biopsy Devices Market Size and Forecast, By End-use, 2018-2032 (USD Million)

  • 7.1 Key trends, by end-use
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Other end-users

Chapter 8 Breast Biopsy Devices Market Size and Forecast, By Region, 2018-2032 (USD Million & Units)

  • 8.1 Key trends, by region
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East & Africa

Chapter 9 Company Profiles

  • 9.1 Stryker Corporation
  • 9.2 Boston Scientific Corporation
  • 9.3 FUJIFILM Holdings Corporation
  • 9.4 Argon Medical Devices, Inc
  • 9.5 Hologic Inc
  • 9.6 Cook Group Incorporated
  • 9.7 Becton, Dickinson and Company (BD)
  • 9.8 Medtronic plc
  • 9.9 Olympus Corporation
  • 9.10 Cardinal Health
  • 9.11 INRAD Inc
  • 9.12 Danaher Corporation
  • 9.13 B. Braun Melsungen AGS